[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

HK1127342A1 - Substituted imidazole derivatives and there use as ptpase inhibitors - Google Patents

Substituted imidazole derivatives and there use as ptpase inhibitors

Info

Publication number
HK1127342A1
HK1127342A1 HK09104978.9A HK09104978A HK1127342A1 HK 1127342 A1 HK1127342 A1 HK 1127342A1 HK 09104978 A HK09104978 A HK 09104978A HK 1127342 A1 HK1127342 A1 HK 1127342A1
Authority
HK
Hong Kong
Prior art keywords
imidazole derivatives
substituted imidazole
ptpase inhibitors
ptpase
inhibitors
Prior art date
Application number
HK09104978.9A
Other languages
English (en)
Inventor
Adnan M M Mjalli
Dharma R Polisetti
James C Quada
Ravindra R Yarragunta
Robert C Andrews
Rongyuan Xie
Govindan Subramanian
Original Assignee
Transtech Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Transtech Pharma Inc filed Critical Transtech Pharma Inc
Publication of HK1127342A1 publication Critical patent/HK1127342A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Hospice & Palliative Care (AREA)
  • AIDS & HIV (AREA)
  • Child & Adolescent Psychology (AREA)
  • Psychiatry (AREA)
  • Dermatology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
HK09104978.9A 2006-01-30 2009-06-03 Substituted imidazole derivatives and there use as ptpase inhibitors HK1127342A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US76325606P 2006-01-30 2006-01-30
PCT/US2007/002675 WO2007089857A2 (en) 2006-01-30 2007-01-30 Substituted imidazole derivatives and their use as ptpase inhibitors

Publications (1)

Publication Number Publication Date
HK1127342A1 true HK1127342A1 (en) 2009-09-25

Family

ID=38042619

Family Applications (1)

Application Number Title Priority Date Filing Date
HK09104978.9A HK1127342A1 (en) 2006-01-30 2009-06-03 Substituted imidazole derivatives and there use as ptpase inhibitors

Country Status (14)

Country Link
US (3) US7723369B2 (xx)
EP (1) EP1991544B1 (xx)
JP (1) JP5180099B2 (xx)
KR (1) KR20080094806A (xx)
CN (1) CN101374835B (xx)
AU (1) AU2007211319B9 (xx)
BR (1) BRPI0707338A2 (xx)
CA (1) CA2637024C (xx)
EA (1) EA019385B1 (xx)
HK (1) HK1127342A1 (xx)
IL (1) IL192557A (xx)
NZ (1) NZ569329A (xx)
WO (1) WO2007089857A2 (xx)
ZA (1) ZA200805648B (xx)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1730118A1 (en) * 2004-02-12 2006-12-13 Transtech Pharma, Inc. Substituted azole derivatives, compositions, and methods of use
AU2007211319B9 (en) * 2006-01-30 2012-05-31 Vtv Therapeutics Llc Substituted imidazole derivatives and their use as PTPase inhibitors
CN102548986A (zh) 2009-06-05 2012-07-04 链接医药公司 氨基吡咯烷酮衍生物及其用途
US20120135997A1 (en) 2009-07-17 2012-05-31 Shionogi & Co., Ltd. Pharmaceutical composition comprising a lactam or benzenesulfonamide compound
JP5398076B2 (ja) * 2009-12-10 2014-01-29 四国化成工業株式会社 ２−（ブロモベンジル）−４−（ブロモフェニル）−５−メチルイミダゾール化合物
JP5398075B2 (ja) * 2010-01-13 2014-01-29 四国化成工業株式会社 ４−（ジクロロフェニル）−２−（４−フルオロベンジル）−５−メチルイミダゾール化合物
EP2612669A4 (en) 2010-08-31 2014-05-14 Snu R&Db Foundation USING THE FÖTAL REPROGRAMMING OF A PPAR AGONIST
AU2011313191A1 (en) 2010-10-08 2013-05-02 Mochida Pharmaceutical Co., Ltd. Cyclic amide derivative
WO2012094580A2 (en) 2011-01-07 2012-07-12 High Point Pharmaceuticals, Llc Compounds that modulate oxidative stress
US9072758B2 (en) 2011-04-28 2015-07-07 Mochida Pharmaceutical Co., Ltd. Cyclic amide derivative
WO2017053706A1 (en) * 2015-09-23 2017-03-30 The General Hospital Corporation Tead transcription factor autopalmitoylation inhibitors
WO2017062468A1 (en) 2015-10-07 2017-04-13 Mitobridge, Inc. Ppar agonists, compounds, pharmaceutical compositions, and methods of use thereof
CA3019014A1 (en) 2016-04-13 2017-10-19 Mitobridge, Inc. Ppar agonists, compounds, pharmaceutical compositions, and methods of use thereof
PL3464272T3 (pl) 2016-06-07 2022-03-28 Jacobio Pharmaceuticals Co., Ltd. Nowe pochodne heterocykliczne użyteczne jako inhibitory SHP2
NZ758458A (en) 2017-03-23 2022-07-29 Jacobio Pharmaceuticals Co Ltd Novel heterocyclic derivatives useful as shp2 inhibitors
WO2020190774A1 (en) 2019-03-15 2020-09-24 The General Hospital Corporation Novel small molecule inhibitors of tead transcription factors
US11058695B2 (en) * 2019-11-08 2021-07-13 Myongji University Industry And Academia Cooperation Foundation Inhibitor of carbapenem-hydrolyzing class D beta-lactamases
AU2021325872A1 (en) * 2020-08-10 2023-03-16 Dana-Farber Cancer Institute, Inc. Substituted 1,2,4-oxadiazoles as small molecule inhibitors of ubiquitin-specific protease 28

Family Cites Families (95)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS63276054A (ja) 1987-05-07 1988-11-14 Hitachi Chem Co Ltd 電子写真感光体
DE69026851T2 (de) 1989-02-14 1996-10-31 Wako Pure Chem Ind Ltd Verfahren zur Erhöhung von Chemilumineszenz
EP0553009B1 (fr) 1992-01-23 1997-06-04 Institut Francais Du Petrole Catalyseur d'alkylation de paraffines
US5510362A (en) 1992-03-13 1996-04-23 Merck, Sharp And Dohme Limited Imidazole, triazole and tetrazole derivatives
US5348969A (en) 1992-04-03 1994-09-20 Bristol-Myers Squibb Company Diphenyloxazolyl-oxazoles as platelet aggregation inhibitors
WO1994008982A1 (en) 1992-10-13 1994-04-28 Nippon Soda Co., Ltd. Oxazole and thiazole derivatives
ATE202571T1 (de) 1993-09-14 2001-07-15 Merck & Co Inc Humane protein-tyrosinphosphatase decodierende cdna
US5616601A (en) 1994-07-28 1997-04-01 Gd Searle & Co 1,2-aryl and heteroaryl substituted imidazolyl compounds for the treatment of inflammation
US6136839A (en) 1995-06-12 2000-10-24 G. D. Searle & Co. Treatment of inflammation and inflammation-related disorders with a combination of a cyclooxygenase-2 inhibitor and a 5-lipoxygenase inhibitor
US5700816A (en) 1995-06-12 1997-12-23 Isakson; Peter C. Treatment of inflammation and inflammation-related disorders with a combination of a cyclooxygenase-2 inhibitor and a leukotriene A4 hydrolase inhibitor
US5753687A (en) 1995-06-19 1998-05-19 Ontogen Corporation Modulators of proteins with phosphotryrosine recognition units
US6388076B1 (en) 1995-06-19 2002-05-14 Ontogen Corporation Protein tyrosine phosphatase-inhibiting compounds
JP3849157B2 (ja) 1995-08-01 2006-11-22 東ソー株式会社 ２−イミダゾリン類の製造法
US6238902B1 (en) 1996-03-22 2001-05-29 Genentech, Inc. Protein tyrosine phosphatases
US5958957A (en) 1996-04-19 1999-09-28 Novo Nordisk A/S Modulators of molecules with phosphotyrosine recognition units
EP0946518A1 (en) * 1996-12-16 1999-10-06 Ontogen Corporation Modulators of proteins with phosphotyrosine recognition units
US5840721A (en) 1997-07-09 1998-11-24 Ontogen Corporation Imidazole derivatives as MDR modulators
GB9715816D0 (en) 1997-07-25 1997-10-01 Black James Foundation Histamine H receptor ligands
FR2767527B1 (fr) 1997-08-25 1999-11-12 Pf Medicament Derives de piperazines indoliques, utiles comme medicaments et procede de preparation
CA2298601A1 (en) 1997-08-28 1999-03-11 Pharmacia & Upjohn Company Inhibitors of protein tyrosine phosphatase
WO1999015529A1 (en) 1997-09-23 1999-04-01 Novo Nordisk A/S MODULES OF PROTEIN TYROSINE PHOSPHATASES (PTPases)
US5972986A (en) 1997-10-14 1999-10-26 G.D. Searle & Co. Method of using cyclooxygenase-2 inhibitors in the treatment and prevention of neoplasia
US6159944A (en) * 1998-02-27 2000-12-12 Synchroneuron, Llc Method for treating painful conditions of the anal region and compositions therefor
US6262044B1 (en) 1998-03-12 2001-07-17 Novo Nordisk A/S Modulators of protein tyrosine phosphatases (PTPASES)
US20020002199A1 (en) 1998-03-12 2002-01-03 Lone Jeppesen Modulators of protein tyrosine phosphatases (ptpases)
EP1077929A1 (en) 1998-05-12 2001-02-28 American Home Products Corporation 2,3,5-substituted biphenyls useful in the treatment of insulin resistance and hyperglycemia
US6699896B1 (en) 1998-05-12 2004-03-02 Wyeth Oxazole-aryl-carboxylic acids useful in the treatment of insulin resistance and hyperglycemia
US20030194745A1 (en) 1998-06-26 2003-10-16 Mcdowell Robert S. Cysteine mutants and methods for detecting ligand binding to biological molecules
ATE451456T1 (de) 1998-07-24 2009-12-15 Merck Frosst Canada Ltd Protein tyrosine phosphatase-1b (ptp-1b)- mangelmaüse und deren verwendungen
US6174874B1 (en) 1998-09-21 2001-01-16 Merck Frosst Canada & Co. Phosphonic acids derivatives as inhibitors of protein tyrosine phosphate 1B (PTP-1B)
WO2000036111A1 (en) 1998-12-11 2000-06-22 Mcgill University Therapeutic and diagnostic uses of protein tyrosine phosphatase tc-ptp
JP4221129B2 (ja) 1999-02-15 2009-02-12 富士フイルム株式会社 含窒素ヘテロ環化合物、有機発光素子材料、有機発光素子
CA2372116A1 (en) 1999-05-14 2000-11-23 Claude Dufresne Phosphonic and carboxylic acid derivatives as inhibitors of protein tyrosine phosphatase-1b (ptp-1b)
ATE257827T1 (de) 1999-07-21 2004-01-15 Hoffmann La Roche Triazolderivate
US6596772B1 (en) 1999-08-27 2003-07-22 Sugen, Inc. Phosphate mimics and methods of treatment using phosphatase inhibitors
US6410556B1 (en) 1999-09-10 2002-06-25 Novo Nordisk A/S Modulators of protein tyrosine phosphateses (PTPases)
CN1414951A (zh) 1999-10-28 2003-04-30 基本治疗公司 药剂排出泵抑制药
DE50009208D1 (de) 1999-11-25 2005-02-17 Ciba Sc Holding Ag Hydroxyphenylvinylthiazole
WO2001046203A1 (en) 1999-12-22 2001-06-28 Merck Frosst Canada & Co. Phosphonic acid biaryl derivatives as inhibitors of protein tyrosine phosphatase 1b (ptp-1b)
US6777433B2 (en) 1999-12-22 2004-08-17 Merck Frosst Canada & Co. Protein tyrosine phosphatase 1B (PTP-1B) inhibitors containing two ortho-substituted aromatic phosphonates
US6448429B1 (en) 1999-12-22 2002-09-10 Merck Frosst Canada & Co. Protein tyrosine phosphatase 1B (PTP-1B) inhibitors containing two ortho-substituted aromatic phosphonates
JP2003518130A (ja) 1999-12-22 2003-06-03 メルク フロスト カナダ アンド カンパニー 蛋白チロシンホスファターゼ１ｂ（ｐｔｐ−１ｂ）阻害薬としてのホスホン酸誘導体
WO2001046205A1 (en) 1999-12-22 2001-06-28 Merck Frosst Canada & Co. Phosphonic acid derivatives as inhibitors of protein tyrosine phosphatase 1b (ptp-1b)
AU2001232833A1 (en) 2000-01-18 2001-07-31 Human Genome Sciences, Inc. Human protein tyrosine phosphatase polynucleotides, polypeptides, and antibodies
TWI284639B (en) 2000-01-24 2007-08-01 Shionogi & Co A compound having thrombopoietin receptor agonistic effect
WO2001061031A2 (en) 2000-02-14 2001-08-23 Ceptyr, Inc. Improved assay for protein tyrosine phosphatases
CA2401984A1 (en) 2000-03-22 2001-09-27 Merck Frosst Canada Inc. Sulfur substituted aryldifluoromethylphosphonic acids as ptp-1b inhibitors
US6627647B1 (en) 2000-03-23 2003-09-30 Boehringer Ingelheim Pharmaceuticals, Inc. Substituted 1-(4-aminophenyl)imidazoles and their use as anti-inflammatory agents
CA2410338A1 (en) 2000-05-22 2001-11-29 Takeda Chemical Industries, Ltd. Tyrosine phosphatase inhibitors
ES2312461T3 (es) 2000-07-06 2009-03-01 Array Biopharma Inc. Derivados de la tirosina como inhibidores de la fosfatasa.
US6613903B2 (en) 2000-07-07 2003-09-02 Novo Nordisk A/S Modulators of protein tyrosine phosphatases (PTPases)
US20020099073A1 (en) 2000-07-07 2002-07-25 Andersen Henrik Sune Modulators of protein tyrosine phosphatases (PTPases)
US20020035137A1 (en) 2000-08-29 2002-03-21 Gang Liu Amino (oxo) acetic acid protein tyrosine phosphatase inhibitors
US6972340B2 (en) 2000-08-29 2005-12-06 Abbott Laboratories Selective protein tyrosine phosphatatase inhibitors
US20020169157A1 (en) 2000-08-29 2002-11-14 Gang Liu Selective protein tyrosine phosphatatase inhibitors
US6627767B2 (en) 2000-08-29 2003-09-30 Abbott Laboratories Amino(oxo) acetic acid protein tyrosine phosphatase inhibitors
US6472545B2 (en) 2000-08-29 2002-10-29 Abbott Laboratories Protein tyrosine phosphatase inhibitors
GB0022079D0 (en) 2000-09-08 2000-10-25 Inst Of Molecul & Cell Biology Novel protein tyrosine phosphatase inhibitor
JP2002114768A (ja) 2000-10-11 2002-04-16 Japan Tobacco Inc ２−（２，５−ジハロゲン−３，４−ジヒドロキシフェニル）アゾール化合物及びそれを含有してなる医薬組成物
US20030108883A1 (en) 2001-02-13 2003-06-12 Rondinone Cristina M. Methods for identifying compounds that inhibit or reduce PTP1B expression
US20030120073A1 (en) 2001-04-25 2003-06-26 Seto Christopher T. Alpha-ketocarboxylic acid based inhibitors of phosphoryl tyrosine phosphatases
JP2002322054A (ja) 2001-04-26 2002-11-08 Dai Ichi Seiyaku Co Ltd 薬剤排出ポンプ阻害薬
US7163932B2 (en) 2001-06-20 2007-01-16 Merck Frosst Canada & Co. Aryldifluoromethylphosphonic acids for treatment of diabetes
US20030064979A1 (en) 2001-06-29 2003-04-03 Hansen Thomas Kruse Method of inhibiting PTP 1B and /or T-cell PTP and/or other PTPases with an Asp residue at position 48
US20030170660A1 (en) 2001-07-11 2003-09-11 Sondergaard Helle Bach P387L variant in protein tyrosine phosphatase-1B is associated with type 2 diabetes and impaired serine phosphorylation of PTP-1B in vitro
US20050014805A1 (en) 2001-10-12 2005-01-20 Chenzhi Zhang Phenyl substituted 5-membered nitrogen containing heterocycles for the treatment of obesity
DK1438310T3 (da) 2001-10-19 2007-03-26 Transtech Pharma Inc Beta-carbolin-derivater som PTP-inhibitorer
US7022730B2 (en) 2001-10-19 2006-04-04 Transtech Pharma, Inc. Bis-heteroaryl alkanes as therapeutic agents
CA2469228A1 (en) 2001-12-03 2003-06-12 Japan Tobacco Inc. Azole compound and medicinal use thereof
JP2003231679A (ja) 2001-12-03 2003-08-19 Japan Tobacco Inc アゾール化合物及びその医薬用途
US6642381B2 (en) 2001-12-27 2003-11-04 Hoffman-La Roche Inc. Pyrimido[5,4-e][1,2,4]triazine-5,7-diamine compounds as protein tyrosine phosphatase inhibitors
US20030180827A1 (en) 2002-01-04 2003-09-25 Aventis Pharma Deutschland Gmbh. Highly sensitive and continuous protein tyrosine phosphatase test using 6,8-difluoro-4-methylumbelliferyl phosphate
US20030215899A1 (en) 2002-02-13 2003-11-20 Ceptyr, Inc. Reversible oxidation of protein tyrosine phosphatases
US6784205B2 (en) 2002-03-01 2004-08-31 Sunesis Pharmaceuticals, Inc. Compounds that modulate the activity of PTP-1B and TC-PTP
ATE529110T1 (de) 2002-03-05 2011-11-15 Transtech Pharma Inc Mono- und bicyclische azolderivate die die interaktion von liganden mit rage hemmen
KR100868587B1 (ko) 2002-04-03 2008-11-12 노파르티스 아게 Ｐｔｐａｓｅ 1ｂ 억제제로서의 5-치환된1,1-디옥소-1,2,5-티아졸리딘-3-온 유도체
BR0309305A (pt) 2002-04-12 2005-02-15 Pfizer Compostos de imidazol como agentes antiinflamatórios e analgésicos
JP4529342B2 (ja) 2002-04-23 2010-08-25 東ソー株式会社 環状アミジニウム有機酸塩の製造方法
JP2003313172A (ja) 2002-04-23 2003-11-06 Tosoh Corp Ｎ−置換イミダゾール化合物の製造方法
US20040009956A1 (en) 2002-04-29 2004-01-15 Dehua Pei Inhibition of protein tyrosine phosphatases and SH2 domains by a neutral phosphotyrosine mimetic
EP1546379A4 (en) 2002-05-23 2007-09-26 Ceptyr Inc MODULATION OF PTP1B SIGNAL TRANSMISSION BY RNA INTERFERENCE
US6849761B2 (en) 2002-09-05 2005-02-01 Wyeth Substituted naphthoic acid derivatives useful in the treatment of insulin resistance and hyperglycemia
EP1402888A1 (en) 2002-09-18 2004-03-31 Jerini AG The use of substituted carbocyclic compounds as rotamases inhibitors
AU2003300447B2 (en) 2002-12-30 2009-09-03 Vertex Pharmaceuticals Incorporated Sulfhydantoins as phosphate isosteres for use as phosphatase inhibitors in the treatment of cancer and autoimmune disorders
US7144911B2 (en) 2002-12-31 2006-12-05 Deciphera Pharmaceuticals Llc Anti-inflammatory medicaments
US7279576B2 (en) 2002-12-31 2007-10-09 Deciphera Pharmaceuticals, Llc Anti-cancer medicaments
WO2004071448A2 (en) 2003-02-12 2004-08-26 Transtech Pharma Inc. Substituted azole derivatives as inhibitors of protein tyrosine phosphatases
WO2004071447A2 (en) 2003-02-12 2004-08-26 Transtech Pharma Inc. Substituted azole derivatives as therapeutic agents
US20040167188A1 (en) 2003-02-14 2004-08-26 Zhili Xin Protein-tyrosine phosphatase inhibitors and uses thereof
KR20050119201A (ko) 2003-04-09 2005-12-20 니뽄 다바코 산교 가부시키가이샤 ５원 헤테로방향족 고리 화합물 및 이의 의약적 용도
US7141596B2 (en) 2003-10-08 2006-11-28 Incyte Corporation Inhibitors of proteins that bind phosphorylated molecules
EP1730118A1 (en) * 2004-02-12 2006-12-13 Transtech Pharma, Inc. Substituted azole derivatives, compositions, and methods of use
ES2397177T3 (es) * 2005-12-08 2013-03-05 Novartis Ag Derivados de 1,2,5-tiazolidina útiles para el tratamiento de condiciones mediadas por proteínas tirosina fosfatasas (PTPASA)
WO2007067614A1 (en) * 2005-12-08 2007-06-14 Novartis Ag l, l, 3-TRI0X0-l, 2, 5-THIADIAZ0LIDINES AND THEIR USE AS PTP-ASES INHIBITORS
AU2007211319B9 (en) * 2006-01-30 2012-05-31 Vtv Therapeutics Llc Substituted imidazole derivatives and their use as PTPase inhibitors

Also Published As

Publication number Publication date
BRPI0707338A2 (pt) 2011-05-03
JP5180099B2 (ja) 2013-04-10
US8404731B2 (en) 2013-03-26
IL192557A (en) 2013-09-30
EP1991544B1 (en) 2018-08-15
AU2007211319B9 (en) 2012-05-31
NZ569329A (en) 2011-09-30
US20070191385A1 (en) 2007-08-16
KR20080094806A (ko) 2008-10-24
WO2007089857A3 (en) 2008-06-26
US20120196906A1 (en) 2012-08-02
EP1991544A2 (en) 2008-11-19
IL192557A0 (en) 2009-02-11
ZA200805648B (en) 2009-09-30
CA2637024C (en) 2013-05-14
US7723369B2 (en) 2010-05-25
CN101374835A (zh) 2009-02-25
AU2007211319A1 (en) 2007-08-09
CA2637024A1 (en) 2007-08-09
AU2007211319B2 (en) 2012-01-19
CN101374835B (zh) 2012-04-25
EA200870218A1 (ru) 2009-02-27
WO2007089857A2 (en) 2007-08-09
US20100113331A1 (en) 2010-05-06
JP2009525340A (ja) 2009-07-09
EA019385B1 (ru) 2014-03-31

Similar Documents

Publication Publication Date Title
HK1127342A1 (en) Substituted imidazole derivatives and there use as ptpase inhibitors
HUS2200052I1 (hu) Imidazotriazinok és imidazopirimidinek mint kinázgátlók
IL194755A0 (en) Pyrimidine derivatives as pi3k inhibitors
IL198247A0 (en) Indazole derivatives useful as l-cpt1 inhibitors
LT2050749T (lt) Pirimidino darinys, kaip pi3k inhibitorius, ir jo panaudojimas
IL192603A0 (en) Thieno-pyridine derivatives as mek inhibitors
IL200047A0 (en) Pyrazole derivatives as 11-beta-hsd1 inhibitors
IL210055A0 (en) Thiophene or thiazole derivatives and their use as pi3k inhibitors
EP2365809B8 (en) Pyrazinopyrazines and derivatives as kinase inhibitors
EP2084139A4 (en) OXAZOLIDINIUM COMPOUNDS AND USE AS HYDRATINE HIBITORS
HK1137756A1 (en) Substituted dihydropyrazolones and use thereof as hif-prolyl-4 -hydroxylase inhibitors hif--4-
IL196000A0 (en) 2-arylindole derivatives as npges-i inhibitors
IL196594A0 (en) Derivatives of 4-trimethylammonium-3-aminobutyrate and 4-trimethylphosphonium-3-aminobutyrate as cpt-inhibitors
HK1191574A1 (zh) 作為 抑制劑的吡唑啉酮衍生物
ZA200905235B (en) Pyrazole derivatives as 11-beta-hsd1 inhibitors

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20200128